Riluzole: 4 agencies, 2012–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused riluzole: all 4 decisive outcomes across 2 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 13.7 years separate the first record, 8 Nov 2012 at PHARMAC (New Zealand), from the most recent, 2026 at PBAC (Australia).
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — SMC (Scotland), AWMSG (Wales) and TLV (Sweden) among them — hold no record for riluzole at all.
The file is active: 2 of 7 records date from 2023 or later.
Against its own class, riluzole is an outlier: 100% of its decisive outcomes were positive, where molecules sharing ATC class N07X average 56%.
1 of these 7 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
PHARMAC (New Zealand) was first to assess riluzole, on 8 Nov 2012; PBAC (Australia) did not open a file until 2026 — an unusually long tail of 13.7 years between the earliest and latest system to look at it.
2 of the 4 agencies here assessed riluzole more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed riluzole.
The full ledger for riluzole reads 4 recommended, 2 other and 1 advice.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 18 Jan 2023 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| NYE METODER (Norway) | 19 Jun 2022 | Behandling av amyotrofisk lateralsklerose (ALS) (se fulle indikasjonstekster under) | introduced | source |
| HAS (France) | 16 Sep 2015 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| HAS (France) | 17 Sep 2014 | Listing renewal (Transparency Committee) | SMR substantial | source |
| PHARMAC (New Zealand) | 13 Feb 2014 | Amending access for amyotrophic lateral sclerosis | PTAC advice: No Formal Recommendation · decision reached | source |
2 further decisions for riluzole, across 2 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 2 further source documents.
Related molecules
- tofersen — divergent outcome (recommended vs not recommended) on a shared indication
- edaravone — divergent outcome (recommended vs not recommended) on a shared indication
- tafamidis — same ATC class N07X — Other nervous system
- vutrisiran — same ATC class N07X — Other nervous system
- pitolisant — same ATC class N07X — Other nervous system
- fampridine — same ATC class N07X — Other nervous system
Coverage: 7 decisions for riluzole from 4 agencies, 2012 to 2026. Data to 7 Sep 2026. ATC class N07X — Other nervous system. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.